# A Study to Evaluate Pre-emptive Treatment for Invasive Candidiasis in High Risk Surgical Subjects

> **NCT01122368** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 252 (actual)

## Conditions studied

- Mycoses

## Interventions

- **DRUG:** micafungin
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01122368
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-13
- **Primary completion:** 2011-12-15
- **Final completion:** 2011-12-15
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2024-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01122368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01122368, "A Study to Evaluate Pre-emptive Treatment for Invasive Candidiasis in High Risk Surgical Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01122368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*